DURAGESIC-37
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-37 is a transdermal extended-release film formulation approved in 1990 for chronic pain management. The product delivers medication continuously through the skin over an extended period. Specific mechanism of action and indications are not disclosed in available data.
LOE Approaching
As LOE approaches, brand team focus will shift from growth to lifecycle extension and managed decline strategies, likely reducing field headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURAGESIC-37 offers limited career growth opportunities given the LOE-approaching lifecycle stage. Positions on this brand are declining as the company transitions resources to newer products.
Brand ManagerField Sales Representative
Worked on DURAGESIC-37 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.